How it works
- RapidVax couples our gp96 platform with the T-cell costimulatory molecule OX40L and a flexible antigen expression system to generate pathogen-specific vaccines.
- Target pathogen antigens are identified, sequenced, and transfected into a common base cell expressing gp96-Ig and OX40L-Ig.
- Pathogen antigens bound to gp96-Ig are released from the cell, stimulating the innate immune toll-like receptors 2 and 4 on Antigen Presenting Cells (APCs) to promote activation and uptake via CD91.
- Processed antigens (peptides) are then presented by APCs to facilitate T cell activation.
- OX40L-Ig released from the RapidVax base cell stimulates OX40 on activated T cells to promote the generation of memory T cells and the expansion of T follicular helper cells that can support B cell antibody production.
RapidVax by the numbers
Advantages of the RapidVax Platform
- Unprogrammed RapidVax vaccines are designed to be manufactured in bulk, stockpiled, and rapidly customized to accelerate time to clinic by harnessing optimizations in preclinical development, safety, and manufacturing.
- Customizable antigen delivery system: target sequences can be transfected into pre-manufactured RapidVax vaccine cells to generate a pathogen-specific immune response.
- Multivalent potential designed to address pathogen heterogeneity.
- Engineered for long-term protection via the stimulation of antibody production and generation of immunological memory.
- A ‘Made in America’ development and manufacturing model to limit potential supply chain vulnerabilities
- Favorable clinical trial safety profile previously observed for our gp96 platform.
- Immunogenicity and prophylactic protection observed in response to gp96/OX40L based vaccines in preclinical models of infectious agents including malaria, HIV/SIV, Zika and SARS-CoV-2 virus.1-5
RapidVax Platform Development
- Infectious Disease: RapidVax leverages our experience developing gp96-based vaccines and couples the immune-activating properties of gp96 and the T cell co-stimulator OX40L with a flexible antigen expression system to generate pathogen-specific vaccines. Platform development and preclinical evaluation of RapidVax as a medical countermeasure are currently underway.